Renal replacement therapy with high-cutoff hemofilters:: Impact of convection and diffusion on cytokine clearances and protein status

被引:134
作者
Morgera, S
Slowinski, T
Melzer, C
Sobottke, V
Vargas-Hein, O
Volk, T
Zuckermann-Becker, H
Wegner, B
Müller, JM
Baumann, G
Kox, WJ
Bellomo, R
Neumayer, HH
机构
[1] Humboldt Univ, Charite, Dept Nephrol, D-1086 Berlin, Germany
[2] Humboldt Univ, Charite, Dept Cardiol, D-1086 Berlin, Germany
[3] Humboldt Univ, Charite, Dept Anesthesiol, D-1086 Berlin, Germany
[4] Humboldt Univ, Charite, Dept Surg, D-1086 Berlin, Germany
[5] Humboldt Univ, Charite, Inst Med Biometr, D-1086 Berlin, Germany
[6] Austin & Repatriat Med Ctr, Dept Intens Care, Melbourne, Vic, Australia
关键词
high-cutoff hemofilter; renal replacement therapy (RRT); cytokine;
D O I
10.1053/j.ajkd.2003.11.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: High-cutoff hemofilters are characterized by an increased effective pore size designed to facilitate the elimination of inflammatory mediators in sepsis. This study compares diffusive versus convective high-cutoff renal replacement therapy (RRT) in terms of cytokine clearance rates and effects on plasma protein levels. Methods: Twenty-four patients with sepsis-induced acute renal failure were studied. A polyflux hemofilter with a cutoff point of approximately 60 kd was used for RRT. Patients were randomly allocated to either continuous venovenous hemofiltration (CVVH) with an ultrafiltration rate of 1 L/h (group 1) or 2.5 L/h (group 2) or continuous venovenous hemodialysis (CVVHD) with a dialysate flow rate of 1 L/h (group 3) or 2.5 L/h (group 4). Interleukin-1 (IL-1) receptor antagonist (IL-1ra), IL-1beta, IL-6, tumor necrosis factor-alpha (TNF-alpha), and plasma proteins were measured daily. Results CVVH achieved significantly greater IL-1ra clearance compared with CVVHD (P = 0.0003). No difference was found for IL-6 (P = 0.935). Increasing ultrafiltration volume or dialysate flow led to a highly significant increase in IL-1ra and IL-6 clearance rates (P < 0.00001). Peak clearances were 46 mL/min for IL-1ra and 51 mL/min for IL-6. TNF-alpha clearance was poor for both RRT modalities. A significant decline in plasma IL-1ra and IL-6 clearance was observed in patients with high baseline levels. Protein and albumin losses were greatest during the 2.5-L/h hemofiltration mode. Conclusion: High-cutoff RRT is a novel strategy to clear cytokines more effectively. Convection has an advantage over diffusion in the clearance capacity of IL-1ra, but is associated with greater plasma protein losses.
引用
收藏
页码:444 / 453
页数:10
相关论文
共 28 条
  • [1] Abraham E, 1998, LANCET, V351, P929
  • [2] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [3] Brunner E, 2002, Nonparametric Analysis of Longitudinal Data in Factorial Experiments
  • [4] Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients
    Dahaba, AA
    Elawady, GA
    Rehak, RH
    List, WF
    [J]. ANAESTHESIA AND INTENSIVE CARE, 2002, 30 (03) : 269 - 274
  • [5] De Vriese AS, 1999, J AM SOC NEPHROL, V10, P846
  • [6] PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL-TRIAL
    DHAINAUT, JFA
    TENAILLON, A
    LETULZO, Y
    SCHLEMMER, B
    SOLET, JP
    WOLFF, M
    HOLZAPFEL, L
    ZENI, F
    DREYFUSS, D
    MIRA, JP
    DEVATHAIRE, F
    GUINOT, P
    [J]. CRITICAL CARE MEDICINE, 1994, 22 (11) : 1720 - 1728
  • [7] RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISHER, CJ
    DHAINAUT, JFA
    OPAL, SM
    PRIBBLE, JP
    BALK, RA
    SLOTMAN, GJ
    IBERTI, TJ
    RACKOW, EC
    SHAPIRO, MJ
    GREENMAN, RL
    REINES, HD
    SHELLY, MP
    THOMPSON, BW
    LABRECQUE, JF
    CATALANO, MA
    KNAUS, WA
    SADOFF, JC
    ASTIZ, M
    CARPATI, C
    BONE, RC
    FREIDMAN, B
    MURE, AJ
    BRATHWAITE, C
    SHAPIRO, E
    MELHORN, L
    TAYLOR, R
    KEEGAN, M
    OBRIEN, J
    SCHEIN, R
    PENA, M
    WASSERLOUF, M
    OROPELLO, J
    BENJAMIN, E
    DELGUIDICE, R
    EMMANUEL, G
    LIE, T
    ANDERSON, L
    MARSHALL, J
    DEMAJO, W
    ROTSTEIN, O
    FOSTER, D
    ABRAHAM, E
    MIDDLETON, H
    PERRY, C
    LEVY, H
    FRY, DE
    SIMPSON, SQ
    CROWELL, RE
    NEIDHART, M
    STEVENS, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23): : 1836 - 1843
  • [8] INFLUENCE OF AN ANTITUMOR NECROSIS FACTOR MONOCLONAL-ANTIBODY ON CYTOKINE LEVELS IN PATIENTS WITH SEPSIS
    FISHER, CJ
    OPAL, SM
    DHAINAUT, JF
    STEPHENS, S
    ZIMMERMAN, JL
    NIGHTINGALE, P
    HARRIS, SJ
    SCHEIN, RMH
    PANACEK, EA
    VINCENT, JL
    FOULKE, GE
    WARREN, EL
    GARRARD, C
    PARK, G
    BODMER, MW
    COHEN, J
    VANDERLINDEN, C
    CROSS, AS
    SADOFF, JC
    GORECKI, J
    DUBIN, HG
    GARNER, C
    KAYE, W
    LANORE, JJ
    MIRA, JP
    ZIMMERMAN, J
    DELLINGER, RP
    TAYLOR, RW
    DAHL, S
    SHELLY, M
    MORTIMER, A
    EDWARDS, JD
    KETT, DH
    QUARTIN, A
    PENA, MA
    BAKKER, J
    ALBERSON, TE
    WALBY, W
    RADCLIFFE, J
    YOUNG, D
    MCQUILLAM, P
    BELLINGHAM, G
    BURMAN, W
    SADOFF, JS
    YOUNG, L
    [J]. CRITICAL CARE MEDICINE, 1993, 21 (03) : 318 - 327
  • [9] Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration
    Heering, P
    Morgera, S
    Schmitz, FJ
    Schmitz, G
    Willers, R
    Schultheiss, HP
    Strauer, BE
    Grabensee, B
    [J]. INTENSIVE CARE MEDICINE, 1997, 23 (03) : 288 - 296
  • [10] Removal of mediators by continuous hemofiltration in septic patients
    Hoffmann, JN
    Faist, E
    [J]. WORLD JOURNAL OF SURGERY, 2001, 25 (05) : 651 - 659